Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Which healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen ...

A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...

is being developed to treat muscle atrophy that sometimes comes with weight loss drugs like Zepbound. Elsewhere, it is ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

More than 800 million adults have diabetes worldwide – almost twice as many as previous estimates have suggested – and more than half of those aged over 30 who have the condition are not receiving ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...